The Pharm Exec staff

Articles

Shire to Relocate More Than 500 Jobs to Lexington, MA

Shire plans to relocate more than 500 positions to Massachusetts from its Chesterbrook, PA, site and establish Lexington, MA, as the company’s US operational headquarters.

EMA Revises Conflict-of-Interest Policy

The European Medicines Agency (EMA) has published its revised policy on handling declarations of interests for scientific-committee members and experts.

Pharma Showing Signs of Stability Despite Patent Cliffs

The pharmaceutical market is beginning to show signs of stability, with a review of 30 leading companies highlighting combined revenues of $718.7 billion in 2013, down just 0.2% from 2012, according to GlobalData.

Actavis Marches Ahead with Acquisition Spree

Actavis’s agreed purchase of Allergan for around $66 billion will help grow the Dublin-based specialty pharma firm to a $22 billion healthcare company in 2015 - a “dramatic elevation”, given the $8.7 billion revenues it recorded in 2013, reports research and consulting firm GlobalData.

EMA States Position on Confidential Information

In response to a letter the European Medicines Agency received from the European Ombudsman on Oct. 27, 2014, the agency is clarifying its policy on commercially confidential information.

J&J Strengthens Infectious Disease Pipeline with Alios Acquisition

Johnson & Johnson completed the acquisition of Alios BioPharma, a privately held clinical-stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash.

Israel Set for “Modest” Pharma Growth

Israel’s pharmaceutical market value will increase from approximately $1.9 billion in 2013 to $2.34 billion, a compound annual growth rate of 2.8%, by 2020, says UK research and consulting firm GlobalData.

Viehbacher Exits Sanofi

Christopher A. Viehbacher resigned as director of Sanofi immediately after its Board of Directors unanimously agreed to remove him as the company’s CEO yesterday. Chairman Serge Weinberg will replace Viehbacher on an interim basis.

NHL Treatment Market Boom Will Be Hindered in EU

The global non-hodgkin lymphoma (NHL) treatment market will increase in value from $5.6 billion in 2013 to $9.2 billion by 2020, according to GBI Research.

Orphan Drug Market to Reach $176 Billion by 2020, Says Report

By 2020, orphan drugs are expected to account for 19 percent of the total share of prescription drug sales excluding generics, reaching $176 billion in annual sales, according to EvaluatePharma’s Orphan Drug Report 2014.